- Home
- DAWN vs THRY Comparison
DAWN vs THRY Comparison
Compare DAWN & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- THRY
- Stock Information
- Founded
- DAWN 2018
- THRY 2012
- Country
- DAWN United States
- THRY United States
- Employees
- DAWN N/A
- THRY N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- THRY Industrial Machinery/Components
- Sector
- DAWN Health Care
- THRY Industrials
- Exchange
- DAWN Nasdaq
- THRY Nasdaq
- Market Cap
- DAWN 624.8M
- THRY 547.4M
- IPO Year
- DAWN 2021
- THRY 2020
- Fundamental
- Price
- DAWN $9.14
- THRY $7.22
- Analyst Decision
- DAWN Strong Buy
- THRY Buy
- Analyst Count
- DAWN 8
- THRY 5
- Target Price
- DAWN $27.63
- THRY $15.50
- AVG Volume (30 Days)
- DAWN 1.9M
- THRY 859.7K
- Earning Date
- DAWN 11-04-2025
- THRY 10-30-2025
- Dividend Yield
- DAWN N/A
- THRY N/A
- EPS Growth
- DAWN N/A
- THRY N/A
- EPS
- DAWN N/A
- THRY 0.40
- Revenue
- DAWN $133,672,000.00
- THRY $779,992,000.00
- Revenue This Year
- DAWN $12.88
- THRY N/A
- Revenue Next Year
- DAWN $48.27
- THRY N/A
- P/E Ratio
- DAWN N/A
- THRY $17.91
- Revenue Growth
- DAWN 31.11
- THRY N/A
- 52 Week Low
- DAWN $5.64
- THRY $6.36
- 52 Week High
- DAWN $16.76
- THRY $20.92
- Technical
- Relative Strength Index (RSI)
- DAWN 71.77
- THRY 24.79
- Support Level
- DAWN $7.11
- THRY $6.36
- Resistance Level
- DAWN $7.62
- THRY $12.57
- Average True Range (ATR)
- DAWN 0.47
- THRY 0.63
- MACD
- DAWN 0.10
- THRY -0.54
- Stochastic Oscillator
- DAWN 72.26
- THRY 13.92
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About THRY Thryv Holdings Inc.
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. Its company is built upon a rich legacy in the marketing and advertising industry. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable SMB clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation, and run their day-to-day operations to save time, compete and win in today's SMB environment. The group has two business segments; Thryv SaaS and Thryv Marketing Services.